Attached files

file filename
8-K - FORM 8-K CREDIT SUISSE PRESENTATION - OMNICARE INCform8-kcreditsuisse.htm

Credit Suisse 20th Annual Healthcare
Conference
November 10, 2011
 
 

 
Forward-Looking Statements
Forward-looking Statements
Certain of the statements made today and listed within the following presentation slides are forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all statements regarding the intent, belief or current
expectations regarding the matters discussed in this presentation. Such forward-looking statements are based on management’s current expectations and
involve known and unknown risks, uncertainties, contingencies and other factors that could cause results, performance or achievements to differ materially from
those stated. The most significant of these risks and uncertainties are described in the Company’s Form 10-K, Form 10-Q and Form 8-K reports filed with the
Securities and Exchange Commission. Investors are cautioned that such statements are only predictions and that actual events or results may differ materially.
These forward-looking statements speak only as of the date this presentation was originally given. We undertake no obligation to publicly release the results of
any revisions to the forward-looking statements made today, to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.
To facilitate comparisons and enhance understanding of core operating performance, certain financial measures have been adjusted from the comparable
amount under Generally Accepted Accounting Principles (GAAP). A detailed reconciliation of adjusted numbers to GAAP is posted in the Investor Relations
section of our Web site at
http://ir.omnicare.com. Additionally, all amounts are presented on a continuing operations basis, unless otherwise stated.
Important Additional Information
On September 7, 2011, Philadelphia Acquisition Sub, Inc. ("Purchaser"), a wholly owned subsidiary of Omnicare, Inc. ("Omnicare"), commenced a tender offer to
purchase all issued and outstanding shares of common stock, par value $0.01 per share (together with the associated preferred share purchase rights, the
"Shares") of PharMerica Corporation ("PharMerica") at a price of $15.00 per Share, net to the seller in cash, without interest and subject to any required
withholding of taxes, upon the terms and subject to the conditions set forth in the Offer to Purchase and in the related Letter of Transmittal (which, together with
any amendments or supplements thereto, constitute the "Offer").  The Offer is scheduled to expire at 5:00 p.m., New York City time, on December 2, 2011,
unless extended.  If the Offer is extended, Omnicare will issue a press release announcing the extension no later than 9:00 a.m., New York City time, on the next
business day following the date the Offer was scheduled to expire.  The Offer is conditioned on, among other things, there being validly tendered and not
withdrawn at least a majority of the total number of Shares outstanding on a fully diluted basis, the board of directors of PharMerica redeeming or invalidating its
"poison pill" stockholder rights plan, receipt of regulatory approvals and other customary closing conditions as described in the Offer to Purchase. The Offer is
not subject to any financing contingencies.
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. The Offer is being made pursuant to a tender offer
statement on Schedule TO (including the Offer to Purchase, Letter of Transmittal and other related tender offer materials) that was filed on September 7, 2011
by Omnicare and Purchaser with the SEC.  These materials, as they may be amended from time to time, contain important information, including the terms and
conditions of the Offer, that should be read carefully before any decision is made with respect to the Offer.  Investors and security holders of PharMerica are able
to obtain free copies of these documents and other documents filed with the SEC by Omnicare through the web site maintained by the SEC at
http://www.sec.gov or by directing a request to the Corporate Secretary of Omnicare, Inc., 100 East RiverCenter Boulevard, Suite 1600, Covington, Kentucky
41011.  Free copies of any such documents can also be obtained by directing a request to Omnicare's information agent, D.F. King & Co., Inc., by phone at
(212) 269-5550 or toll-free at (800) 769-7666 or by email at info@dfking.com.
2
 
 

 
Omnicare Today
3
 
 

 
Omnicare Today…
A Leading Provider of Pharmacy Services
 Long-term care pharmacy
  Pharmacy services for skilled nursing,
 assisted living, chronic care and other settings
  47 states, District of Columbia and Canada
  Dispenses over 110 million prescriptions/year
  Industry leader
 Specialty care
  Supports patients, providers, care-givers,
 nurses, physicians and bio-pharmaceutical
 companies
  Dispenses over 8 million prescriptions/year
  Emerging provider with growth rates
 outpacing industry average
Long-term care pharmacy and specialty care provide two attractive platforms for growth
4
 
 

 
Operating Objectives
5
 
 

 
Transitioning to an Operations-Driven Company
Focus on Three Core Operating Objectives
 Establish consistent organic growth in our
 Long-Term Care Group
 Reposition Specialty Care Group for an
 elevated level of growth
 Create more standardization across the
 company
6
 
 

 
Transitioning to an Operations-Driven Company
Establishing Consistent Organic Growth in LTC
 Focus on customer retention
  Revamp corporate culture, increase employee engagement
  Align incentive programs with customer service to improve retention
  Reshape the organization to bring it closer to the customer
  Organization-wide focus on the customer
  Objective is to a achieve 95% customer retention rate
 Investments being made to accelerate sales results
  Reorganization of sales force - improve coordination of selling process
  Investments in sales tools, training programs
  Deploy resources in attractive markets
  Refine go-to-market message
7
Omnicare is further along with efforts to improve service delivery,
with sales and marketing investments now underway
 
 

 
3Q11 YTD net organic bed loss is 49.5% lower than 3Q10 YTD
Transitioning to an Operations-Driven Company
Establishing Consistent Organic Growth in LTC
8
43.2%
better than
2010
 
 

 
Transitioning to an Operations-Driven Company
Repositioning Specialty Care Group for Elevated Growth
9
 
 

 
Transitioning to an Operations-Driven Company
Repositioning Specialty Care Group for Elevated Growth
Omnicare specialty care growth has been robust…and opportunities
exist to further accelerate growth through:
Continued improvements to the organizational structure
  Investments made in manufacturer-focused sales organization
  Platform-specific experts added to expand breadth of knowledge
Expanding into other specialty-focused platforms
Penetrating additional disease states in specialty pharmacy platform
  Primary disease states currently multiple sclerosis and oncology
Leveraging long-term care business to create new opportunities
Two-year CAGR(1) for Omnicare’s specialty care businesses > 20%
(1) Quarterly revenues based on fourth quarter 2009 results for Advanced Care Scripts, RxCrossroads and excelleRx
 (as compared with third-quarter 2009 results)
10
 
 

 
Transitioning to an Operations-Driven Company
Creating More Standardization
 Technological advancements
  On-site medication availability technology
 (pilot)
 Establish benchmarks
  Performance targets drives greater
 efficiencies
  Six Sigma quality standards
 Strategic Sourcing
  Leverage assets to maximize efficiencies
11
 
 

 
Acquisition Program
Opportunities to Leverage Scale
12
 Omnicare’s scalable platform makes LTC acquisitions attractive
  Leverage synergies through direct purchasing of generics
  Utilize hub-and-spoke network and automation/technology platforms
  Improvements in customer retention efforts lowers customer attrition risk
 Acquisitions approached in disciplined manner with early involvement of
 operators
 PharMerica proposal
  Believe PharMerica to be an excellent fit
  Believe outstanding offer to be a compelling value for PharMerica investors
  Consistent with the country’s ongoing efforts to lower healthcare costs
 Also considering acquisitions to fill-out the specialty care portfolio
Evaluating acquisition opportunities in Long-Term Care and Specialty Care
 
 

 
Industry Outlook
13
 
 

 
Demographic Trends
Aging Population Shaping US Healthcare System
 Life expectancy continues to lengthen
Source: U.S. Census Bureau
14
Persons over age 85 more likely to reside in a skilled nursing facility
 
 

 
Pharmaceutical Market
Trends
 Development and utilization of specialty drugs increasing
 Major market shift to generic drugs
15
Pharmaceutical Market Share(1) by Drug Type
Conventional
Drugs, 72%
Other, 19%
(1) Source: EvaluatePharma
 
 

 
Brand to Generic Drugs
Increasing Utilization of Generics
(1) Omnicare’s generic prescriptions dispensed as a percent of total scripts
16
Generic dispensing rate has increased every quarter since 2006
 
 

 
Major Shift to Generic Drugs
Typical Life Cycle of Nonexclusive Generic Drug
NOTE: Graph is for illustrative purposes only. Not representative of every generic drug, as each generic drug has unique
 characteristics.
17
Lowers sales but stronger gross profit margin and dollars over time
 
 

 
(1) All generic launches are subject to change due to litigation or pediatric exclusivity.
(2) Drugs already launched shown in gray and italics
2011
2012
2013
Fazaclo
Actos
Aciphex
Femara
Diovan
Asacol
Levaquin
Geodon
Avodart
Uroxatrol
Invega
Cymbalta
Vancocin Caps
Lexapro
Humalog
Xalatan
Plavix
Lupron Depot
Zyprexa
Provigil
Niaspan SR
Gabitril
Seroquel
Oxycontin
Lipitor
Singulair
Renagel
Primaxin Inj
Xopenex
Travatan
2011-2013 Potential Patent Expirations(1)(2)
Geriatric Market
18
 
 

 
Regulatory Outlook
19
 
 

 
Regulatory Environment
Current Issues
 Short-cycle dispensing
  Requires dispensing branded drugs bi-weekly, for oral-solids only, to Part D beneficiaries in
 skilled nursing facilities
  Delayed effective date to 1/1/13, reducing impact as more generics enter the market
 AMP-Based Federal Upper Limits (FUL)
  No less than 175% of the weighted average manufacturer’s price (“AMP”)
  Effective 10/1/10, although partial draft FUL lists have only recently been published
  Applies to reimbursement on multi-sourced generics for certain payors
  Omnicare has significantly reduced its exposed by restructuring contracts
  Omnicare believes draft AMP-based FUL’s are highly inconsistent and contain multiple
 errors
  No timetable for implementation has been issued
20
Anticipate small negative to Omnicare in 2013;
we believe we are best positioned among peers
Negative impact to Omnicare expected
 
 

 
Regulatory Environment
Current Issues
 Consultant pharmacist separation
 (consideration only)
  Separation of consultant pharmacist from
 the long-term care pharmacy
  CMS believes this model would lower
 prescriptions
  Omnicare anticipates higher overall
 healthcare costs due to inefficient model
  Reduces coordination of care efficiencies
  New Jersey benchmark suggests that
 utilization would increase in this proposed
 model
Anticipate no material impact to Omnicare
21
 
 

 
Financial Overview
22
 
 

 





Third Quarter 2011 Highlights
 Gross profit increased 2.9% sequentially to $346.1M on 0.7% decrease in sales
  Gross margin sequentially higher by 79 bps to 22.4%, reflecting higher generic
 dispensing rates
 Cash flows from continuing operations of $167.1M increased 22.1% sequentially
 and 43.7% over 3Q10.
  Adjusted EBITDA(1) increased 7.5% sequentially to $157.2 million
 Adjusted EPS(1) of $0.54 as compared to 2Q11 of $0.50 and 3Q10 of $0.53
 Scripts flat versus 3Q10; 0.7% lower than 2Q11
  Utilization weaker, consistent with industry
  Generic dispensing rate increased 60 basis points sequentially
 Qtr. ending number of beds/patient assistance program (PAP) patients up 2,000
 sequentially
  Beds 10,000 higher; PAP patients down 8,000
  Net organic bed loss of 8,000 decreased 27.3% from 2Q11 organic net bed loss of
 11,000, and decreased 46.7% from 3Q10 organic net bed loss of 15,000
 $54.6 million returned to shareholders through share repurchases and dividends
23
(1) Excludes special items. A reconciliation of non-GAAP information has been attached to our press release and is also available on our Web site under
 ‘Supplemental Financial Information’ from the ‘Investors’ page
.
 
 

 
(1) Excludes discontinued operations.
(2) Excludes special items. A reconciliation of certain non-GAAP information is available on Omnicare’s Web site under ‘Supplemental
 Financial Information’ from the ‘Investors’ page.
Financial Performance
Four Quarter Progression (in $ millions, except per share data)
24
 
 

 
Focus on Cash Flow
25
 17.5% cash flow from operations yield based on current market
 capitalization(2)
Quarterly Cash Flows from Continuing Operations(1) 2011 vs. 2010 (in $ millions)
(1) Excludes discontinued operations.
(2) As of the close of trading on 10/31/2011
 
 

 
26
(1) Through the first nine months of 2011, Omnicare repurchased $200 million of 6.125% senior subordinated notes due 2013 and $425 million of 6.875%
 senior subordinated notes dues 2015. During the first nine months of 2010, Omnicare repurchased $125 million of senior term A loans due 2010 and $225
 million of 6.75% senior subordinated notes due 2013.
(2) Cumulative % Returned = (Dividends Paid + Share Repurchases) / 12/31/10 Market Capitalization of $2,961.0 million.
 Repurchased an additional 1.8 million
 shares ($50.1 million) during 3Q11 (in
 addition to 2.3 million shares
 repurchased through 2Q11 and 4.4
 million repurchased in 2010)
 $78.9 million of authorization remaining
 under current share repurchase program
 as of September 30, 2011.
 3Q11 dividend of $0.04 per share
 Higher CapEx from technology
 investment
 
 

 
(1) Assumes convertible debentures due 2035 are put to the company in 2015 with related tax recapture included and debt amounts shown
 are exclusive of unamortized debt discount.
Capital Structure
Goal is to spread out maturities to limit refinancing risk
27
 
 

 
Omnicare’s Fundamental Value Drivers
28
 
 

 

Credit Suisse 20th Annual Healthcare
Conference
November 10, 2011